News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Neuroendocrine Tumors
July 26, 2018
Afinitor Promising in Neuroendocrine Tumors Originating in GastrointestinalTract
Charles H. Weaver, MD
July 4, 2018
Sutent Delays Progression of Pancreatic Neuroendocrine Tumors
Charles H. Weaver, MD
July 3, 2018
Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET)
Charles H. Weaver, MD
July 1, 2018
Afinitor and Temodar Active against Pancreatic Neuroendocrine Tumors
Charles H. Weaver, MD
June 29, 2018
Afinitor Approved for Pancreatic Neuroendocrine Tumors
Charles H. Weaver, MD
June 14, 2018
Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors
Charles H. Weaver, MD
June 1, 2018
CancerConnect Launches On line Community for Patients with Neuroendocrine Tumors
Charles H. Weaver, MD
December 10, 2009
Delcath Receives Orphan Drug Designation for Treatment of Neuroendocrine Tumors
Charles H. Weaver, MD
Previous Page
1
2
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
